Cancer patients on PD-1 inhibitors at risk of arthritis

Rheumatic adverse events 'relatively common' on the treatment, researchers say

Patients who respond well to programmed cell death protein 1 (PD-1) inhibitor therapy for cancer, may be at increased risk of developing arthritis as an adverse effect, an Australian study suggests.

A retrospective chart review examined 244 treatment episodes involving the PD-1 inhibitors nivolimumab or pembrolizumab that were initiated in patients at a Melbourne cancer centre before January 2017.

“Patients who had an adverse rheumatic event when on PD-1 therapy had eleven times the chance of having a good oncological response,” lead